מיקוטיל 300 וטרינרי
euromar ltd - tilmicosin as phosphate - תמיסה להזרקה - tilmicosin as phosphate 300 mg / 1 ml
בינוקריט 2000 יחבל 1 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
בינוקריט 10000 יחבל 1 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 10000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
בינוקריט 40000 יחבל 1 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 40000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
פראלואנט 150 מגמל
sanofi israel ltd - alirocumab - תמיסה להזרקה - alirocumab 150 mg / 1 ml - alirocumab
פראלואנט 75 מגמל
sanofi israel ltd - alirocumab - תמיסה להזרקה - alirocumab 75 mg / 1 ml - alirocumab
אונדנסטרון אינובמד להזרקה 2 מ"ג/מ"ל
inovamed ltd - ondansetron as hydrochloride dihydrate 2 mg / 1 ml - solution for injection - ondansetron - adults:ondansetron inovamed is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. ondansetron inovamed is indicated for the prevention and treatment of post-operative nausea and vomiting (ponv). paediatric population:ondansetron inovamed is indicated for the management of chemotherapy-induced nausea and vomiting (cinv) in children aged ?6 months, and for the prevention and treatment of ponv in children aged ?2 years.
פלונוסטרון טבע ® 0.25 מ"ג/5 מ"ל
teva pharmaceutical indust.ltd - palonosetron as hydrochloride 0.05 mg / 1 ml - solution for injection - palonosetron - prevention of chemotherapy - induced nausea and vomiting (cinv).
פרוטוזול
kamada ltd - aprotinin 10000 kiu / 1 ml - solution for injection - aprotinin - protosol is used in adults in the treatment and prophylaxis of disorders in which inhibition of proteolytic enzymes is indicated: for the early treatment of states of shock. for the prevention of postoperative or post-traumatic complications. to reduce major blood loss in patients undergoing surgery involving cardiopulmonary bypass.
אפורציו iu 10,000
salomon,levin & elstein ltd - epoetin theta (r-huepo) 10000 iu / 1 ml - solution for injection - erythropoietin - - treatment of symptomatic anaemia associated with chronic renal failure in adult patients.- treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.